Comparative Effectiveness of Hangeshashinto and Ramosetron for the Treatment of Irritable Bowel Syndrome with Diarrhea
Digestion · 01.06.2026 · 1-11
DOI: 10.1159/000552817 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestion, online erschienen am 01.06.2026. Verfasst von Koji Nishida und 10 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan. Die Arbeit nennt 47 Literaturangaben.
Abstract (Originalsprache)
Introduction
Evidence-based pharmacological options for irritable bowel syndrome with diarrhea (IBS-D) remain limited, and complementary approaches are of interest. We evaluated the real-world effectiveness of hangeshashinto (TJ-14), ramosetron, and their combination in patients with IBS-D or mixed-type IBS (IBS-M).
Methods
This retrospective observational pilot study included 56 patients with IBS-D/IBS-M treated for 4 weeks with ramosetron (n = 12), hangeshashinto (n = 31), or combination therapy (n = 13). Symptoms were assessed at baseline and week 4 using the Izumo scale. Within-group changes were examined using nonparametric tests. To address baseline imbalances, pairwise propensity score analyses were performed using Average Treatment effect on the Treated (ATT) weighting with weighted outcome regression adjusting for pretreatment Izumo scores and prespecified covariates.
Results
All groups showed improvement in Izumo symptom scores over 4 weeks. In ATT-weighted analyses, follow-up Izumo scores were comparable between hangeshashinto and ramosetron (adjusted mean difference [Hangeshashinto − Ramosetron] −0.269, 95% CI: −1.402 to 0.863). Combination therapy was associated with lower follow-up scores than ramosetron alone (adjusted mean difference [Combination − Ramosetron] −1.849, 95% CI: −3.571 to −0.127), while the comparison with hangeshashinto alone did not reach statistical significance (adjusted mean difference [Combination − Hangeshashinto] −0.845, 95% CI: −1.763 to 0.074). Higher pretreatment Izumo scores were independently associated with greater improvement.
Conclusion
In this exploratory real-world analysis, hangeshashinto showed short-term symptom improvement similar to ramosetron, and combination therapy was associated with lower follow-up symptom scores than ramosetron monotherapy in propensity score-adjusted analyses. However, given the retrospective design, small sample size, and inconsistent findings across analytical approaches, these results should be interpreted cautiously and warrant confirmation in larger prospective studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan.
- Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan, yuki.hirata.ln@ompu.ac.jp.
- Murano Clinic, Osaka City, Japan.
Zitieren
APA
Nishida, K., Hirata, Y., Murano, M., Mitooka, H., Sugishima, S., Nakazawa, K., Koshiba, R., Kakimoto, K., Miyazaki, T., Nakamura, S., & Nishikawa, H. (2026). Comparative Effectiveness of Hangeshashinto and Ramosetron for the Treatment of Irritable Bowel Syndrome with Diarrhea. Digestion, 1-11. https://doi.org/10.1159/000552817
Vancouver
Nishida K, Hirata Y, Murano M, Mitooka H, Sugishima S, Nakazawa K, et al. Comparative Effectiveness of Hangeshashinto and Ramosetron for the Treatment of Irritable Bowel Syndrome with Diarrhea. Digestion. 2026:1-11. doi:10.1159/000552817
BibTeX
@article{Nishida2026,
author = {Nishida, Koji and Hirata, Yuki and Murano, Mitsuyuki and Mitooka, Hideaki and Sugishima, Suzune and Nakazawa, Kei and Koshiba, Ryoji and Kakimoto, Kazuki and Miyazaki, Takako and Nakamura, Shiro and Nishikawa, Hiroki},
title = {Comparative Effectiveness of Hangeshashinto and Ramosetron for the Treatment of Irritable Bowel Syndrome with Diarrhea},
journal = {Digestion},
year = {2026},
pages = {1--11},
doi = {10.1159/000552817}
}
EUVIMED